Investigation Launch into Owlet, Inc.
Recently, a significant investigation has come to light regarding Owlet, Inc., previously known as Sandbridge Acquisition Corporation (NYSE: OWLT). This inquiry is being led by the prominent law firm Kahn Swick & Foti, LLC, represented by former Louisiana Attorney General, Charles C. Foti, Jr., Esq. KSF is known for its dedicated advocacy in protecting the interests of investors, focusing now on Owlet's operations and corporate governance.
The FDA Warning and Legal Consequences
In October 2021, Owlet made headlines after receiving a stern warning letter from the U.S. Food and Drug Administration (FDA). The letter outlined serious concerns regarding the Owlet Smart Sock product, which has been marketed for monitoring critical health metrics like blood oxygen saturation and pulse rate. The FDA stated that the product should be classified as a medical device and required premarket clearance, a certification that Owlet had not secured. This misstep has raised red flags about the potential risks to consumers and the legality of product distribution.
Impact of the Securities Class Action Lawsuit
Following the FDA notice, Owlet and some of its executives became embroiled in a securities class action lawsuit. This legal case accuses them of failing to disclose crucial information to investors, which constitutes a violation of federal securities laws. The court overseeing the lawsuit has recently decided to allow it to proceed, denying Owlet's motion to dismiss the key claims. Such a development could have serious implications for the company, especially in the context of investor confidence and market reputation.
Kahn Swick & Foti’s Focus
KSF’s investigation is especially interested in determining whether the officers and directors of Owlet, Inc. neglected their fiduciary responsibilities towards shareholders. This inquiry is vital to understanding the broader implications of Owlet's actions and governance for its financial backers. If negligence or wrongdoing is uncovered, shareholders may have legal recourse against the company and its leaders.
How to Assist the Investigation
Shareholders or individuals with relevant information related to this investigation are encouraged to come forward. Kahn Swick & Foti ensures that any discussions will be held confidentially and without any financial obligation on the part of the informer. Claimants can reach out to KSF toll-free at 1-833-938-0905 to share insights or to learn more about their legal rights regarding their investments in Owlet.
About Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC is recognized as a leading securities litigation law firm in the United States. With their roots in protecting investors' rights, KSF represents a diverse array of clients ranging from public institutional investors to individual retail investors. Their mission is to recover losses stemming from corporate misconduct and to facilitate accountability among publicly traded companies. KSF operates across several states, including New York, California, Louisiana, New Jersey, and Delaware.
Frequently Asked Questions
What is the nature of the investigation into Owlet?
The investigation focuses on whether Owlet’s officers and directors breached fiduciary duties or violated laws in light of FDA warnings regarding their products.
How did the FDA respond to Owlet's products?
The FDA issued a warning stating that Owlet's Smart Sock requires regulatory approval as it qualifies as a medical device, which the company failed to obtain.
What legal actions have been taken against Owlet?
Following the FDA’s warning, a securities class action lawsuit was filed against Owlet's executives for failing to disclose critical information to investors.
Who can assist with the investigation?
Kahn Swick & Foti encourages any shareholders with information or who have held Owlet shares long-term to reach out for support or to discuss their legal options.
What is Kahn Swick & Foti's expertise?
KSF specializes in securities litigation, helping clients recover losses caused by corporate fraud or misconduct, with a strong focus on investor protection.
